NUVESSA and VANDAZOLE both contain metronidazole and are prescribed for bacterial vaginosis, but they are not two labels for the same vaginal-gel package. NUVESSA is a 1.3% single-dose, prefilled-applicator product, while VANDAZOLE is a 0.75% vaginal gel associated with a multi-day regimen. Their different concentrations, packages and instructions are the center of this comparison.
Both names can appear alongside generic metronidazole products in U.S. drug databases. Generic status must be interpreted at the level of the exact dosage form and strength. In particular, FDA approved ANDA 216795 for metronidazole vaginal gel 1.3% referencing Nuvessa in March 2024. That regulatory fact does not mean a specific pharmacy has a generic in stock, nor does it make 0.75% gel an equivalent one-dose substitute.
For the products separately, visit Nuvessa 1.3% brand guide and Vandazole 0.75% brand guide. This article is designed to help identify the correct order, package and dispensing requirements rather than recommend switching regimens. The two brands should be selected only through a clinician’s diagnosis and valid prescription.
This comparison starts with the product, route and indication rather than a promise that one medicine is faster, stronger or cheaper. The differences in the matrix help a patient identify exactly what a clinician has prescribed for Nuvessa vs Vandazole. They are not a self-treatment chart, and the actual product label should control administration.
Both rows use metronidazole, but the 1.3% Nuvessa applicator is not a concentration-adjusted version of Vandazole 0.75%. The FDA-approved 1.3% generic belongs to the Nuvessa product category, not to a broad category that includes every vaginal gel. The pharmacist needs the exact authorized formulation and cannot infer substitution from the shared active ingredient.
| Comparison point | NUVESSA | VANDAZOLE |
|---|---|---|
| Product | NUVESSA | VANDAZOLE |
| Active ingredient | Metronidazole | Metronidazole |
| Concentration | 1.3% vaginal gel | 0.75% vaginal gel |
| Package concept | Single-dose prefilled applicator | Multi-day vaginal gel and applicators |
| Labeled application pattern | Once, at bedtime | Multiple-day course under label |
| FDA-approved corresponding generic | ANDA 216795 approved (does not imply stock) | Approved generic 0.75% vaginal gel products exist |
| Pharmacy check | 1.3% plus specific unit | 0.75% plus correct applicators/course |
| Equivalent by matching ingredient alone? | No | No |
A 1.3% gel contains a different concentration of metronidazole from a 0.75% gel. That number alone does not explain the entire difference, because a course is defined by the package, delivered amount and instructions together. Nuvessa is formulated and labeled for one vaginal administration; Vandazole follows its own multi-day instructions.
Patients should not calculate a homemade conversion, use more or less 0.75% gel to imitate Nuvessa, or reuse a 1.3% applicator. If the prescription indicates a particular brand, strength or dosing course, those details need to be resolved with the dispensing pharmacist.
A historic claim that no Nuvessa generic has FDA approval is outdated. FDA’s March 18, 2024 approval letter for ANDA 216795 explicitly identifies a therapeutically equivalent metronidazole vaginal gel 1.3% referencing Nuvessa. The FDA’s conclusion addresses regulatory equivalence, not live inventory, pricing or a guaranteed substitution in every state or prescription situation.
Vandazole-related generic comparisons also must match vaginal route, strength and relevant therapeutic-equivalence records. A gel with a 0.75% number on the package can be a skin-only product for rosacea, so looking at concentration without route is insufficient.
Nuvessa labeling calls for a single-dose prefilled applicator administered intravaginally at bedtime. The patient should receive product-specific information for that packaging. Vandazole belongs to a different course structure, and the pharmacy should provide the applicators and quantity intended for the prescribed regimen.
An online listing with just the word metronidazole or even vaginal gel may omit the critical brand or concentration. Ask the pharmacist to confirm the exact item on the dispensing record before payment or pickup, particularly when a product is displayed as a generic alternative.
Although a skin rosacea gel can carry the same active ingredient and even a similar concentration, it is not a vaginal medicine. An oral tablet is likewise a different formulation and route. This is a meaningful safety distinction when product catalogs mix all metronidazole entries in search results.
The 0.75% vaginal gel product guide explains its exact identity; vaginal versus topical gel addresses route errors. If a dispensed product does not clearly say vaginal use, contact the pharmacist before administration.
Both vaginal products have metronidazole-related and formulation-specific precautions. A one-time application does not eliminate adverse-event risk, and a multi-day course is not by itself evidence of a worse treatment. Prior reactions, age, pregnancy or other clinical factors can affect the intended choice.
If discharge, odor or irritation persists, the clinician may reconsider the diagnosis or treatment response. Repeating a brand, using leftover gel or changing concentration without care can mask yeast infection or another cause of symptoms.
To compare cost fairly, ask for the total prescribed Nuvessa package versus the total prescribed Vandazole course, accounting for insurance requirements and dispensing terms. The Nuvessa generic approval may be relevant to a formulary discussion, but availability and coverage must be checked for an identified product rather than assumed from approval alone.
The Nuvessa price and coverage guide and Vandazole price factors cover these separate cost decisions. This comparison intentionally avoids actual pharmacy quotes or promises of stock.
A patient who receives a prescription for Nuvessa may see a pharmacy result labeled generic metronidazole vaginal gel. The important follow-up is whether the generic is specifically the FDA-approved 1.3% equivalent, not simply any metronidazole gel. The generic vaginal metronidazole guide explains why strength-specific and route-specific identity is important. A 0.75% Vandazole-related product must remain distinct.
Conversely, a patient prescribed Vandazole might see the 1.3% Nuvessa brand described as requiring only one administration. That convenience does not create permission to modify the prescribed course. A clinician should assess whether any change is medically suitable, and the pharmacy should issue the exact authorized label rather than modify package directions.
Generic approval, retail launch and plan coverage move on different timelines. This is why vaginal product availability checks and the 0.75% gel cost guide answer questions that FDA approval records alone cannot resolve. Neither a listing nor a prior coupon should be described as a live offer.
Begin with the specific question answered on this page: Named branded single-dose 1.3% versus multiple-dose 0.75% vaginal gel comparison. Do not use a comparison page to diagnose an infection or choose an antibiotic without a licensed clinician. Identify the medical purpose of the current prescription and check that the intended medicine, dosage form and route are clear enough for the dispensing pharmacist to verify.
For Nuvessa check 1.3% and the single prefilled applicator; for Vandazole check 0.75% and the appropriate multi-day package. A suggestion that a generic may be used requires a strength-specific, route-specific review rather than a bare ingredient match. FDA approval of the 1.3% generic is not a statement that it is stocked nearby.
Both contain metronidazole, but the concentrations, presentations and labeled administration courses differ.
Yes. Its label describes a single vaginal administration with a prefilled applicator.
No. Vandazole is a distinct vaginal-gel product with a multi-day labeled course.
No. Do not change amount, strength or regimen without prescriber authorization.
Yes. ANDA 216795 for metronidazole vaginal gel 1.3% was approved in March 2024; this does not establish retail availability.
No. MetroGel for rosacea is a skin medicine, not an intravaginal formulation.
Not necessarily. Different labeled courses cannot be ranked on concentration alone.
A substitution needs to match legal and product-specific requirements; verify the exact formulation and prescription.
Yes. Both are prescription vaginal metronidazole products in the United States.
Compare total prescribed packages and actual pharmacy or insurer terms, not just concentration or tube size.